文献速递血栓与止血

罗米司亭治疗成人新诊断或持续性免疫性血小板减少症(ITP)长达1年及慢性ITP超过1年的患者:已完成罗米司亭研究汇总数据的亚组分析

Romiplostim in adult patients with newly diagnosed or persistent immune thrombocytopenia (ITP) for up to 1 year and in those with chronic ITP for more than 1 year: a subgroup analysis of integrated data from completed romiplostim studies.
PubMed 文献 · Br J Haematol · 2019-02-21

该分析汇总9项研究数据,纳入一线治疗失败的成人ITP患者,按病程≤1年(n=311)或>1年(n=726)分组,比较罗米司亭与安慰剂/标准治疗。罗米司亭组血小板反应患者发生率在病程≤1年者为74%(204/277)、>1年者为71%(450/634),均高于安慰剂/标准治疗组的18%(6/34)和9%(8/92);罗米司亭组严重不良事件和出血发生率更低,血栓事件发生率相似。

要点

  • 罗米司亭组血小板反应发生率在ITP≤1年为74%(204/277),>1年为71%(450/634)。
  • 安慰剂/标准治疗组血小板反应发生率在ITP≤1年为18%(6/34),>1年为9%(8/92)。
  • 研究≥9个月的患者中,ITP≤1年者16%、>1年者6%停用罗米司亭后维持无治疗缓解。

核心结论

  • 罗米司亭与安慰剂/标准治疗安全性相似,在ITP≤1年或>1年患者中均提高血小板计数,且ITP≤1年者无治疗缓解更多。

研究设计与样本

  • 汇总9项已完成研究的汇总数据分析,纳入一线治疗失败的成人ITP患者,按病程≤1年(n=311)或>1年(n=726)分组,接受罗米司亭、安慰剂或标准治疗。

主要发现

  • 血小板反应(≥75%的测量次数)患者发生率:罗米司亭组ITP≤1年为74%(204/277),>1年为71%(450/634);安慰剂/标准治疗组ITP≤1年为18%(6/34),>1年为9%(8/92)。
  • 研究≥9个月的患者中,停用罗米司亭后维持血小板计数≥50×10^9/L且≥6个月无ITP治疗(无治疗缓解)者:ITP≤1年为16%,>1年为6%。
  • 无论ITP病程,罗米司亭组严重不良事件和出血发生率均低于安慰剂/标准治疗组,血栓事件发生率相似。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The thrombopoietin receptor agonist romiplostim is approved for second-line use in chronic immune thrombocytopenia (ITP), but its effects in patients with ITP for ≤1 year are not well characterized. This analysis of pooled data from 9 studies included patients with ITP for ≤1 year (n = 311) or >1 year (n = 726) who failed first-line treatments and received romiplostim, placebo or standard of care. In subgroup analysis by ITP duration, patient incidences for platelet response at ≥75% of measurements were higher for romiplostim [ITP ≤1 year: 74% (204/277); ITP >1 year: 71% (450/634)] than for placebo/standard of care [ITP ≤1 year: 18% (6/34); ITP >1 year: 9% (8/92)]. Of patients with ≥9 months on study, 16% with ITP ≤1 year and 6% with ITP >1 year discontinued romiplostim and maintained platelet counts ≥50 × 109 /l for ≥6 months without ITP treatment (treatment-free remission). Independent of ITP duration, rates of serious adverse events and bleeding were lower with romiplostim than placebo/standard of care and thrombotic events occurred at similar rates. In this analysis, romiplostim and placebo/standard of care had similar safety profiles and romiplostim increased platelet counts in patients with either ITP ≤1 year or ITP >1 year, with more treatment-free remission in those with ITP ≤1 year.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Kuter DJ, Newland A, Chong BH, et al. Romiplostim in adult patients with newly diagnosed or persistent immune thrombocytopenia (ITP) for up to 1 year and in those with chronic ITP for more than 1 year: a subgroup analysis of integrated data from completed romiplostim studies. Br J Haematol. 2019. PMID: 30793285. doi:10.1111/bjh.15803

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。